Form 4: Mural Oncology Legal Officer Sells Shares Under Pre-Arranged Plan
Insider Stock Sale
Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology plc, sold 2,572 ordinary shares for a weighted average price of $2.48 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology plc (MURA), reported a transaction.
- On July 22, 2025, 2,572 ordinary shares were sold.
- The shares were sold at a weighted average price of $2.48 per share, with individual transaction prices ranging from $2.46 to $2.51.
- The sale was executed automatically pursuant to a Rule 10b5-1 trading arrangement, which was established by the Reporting Person on September 20, 2024.
- Following the reported transaction, Maiken Keson-Brookes beneficially owns 68,834 ordinary shares, which includes 62,203 unvested restricted stock units.
Sentiment
Score: 5
Explanation: The filing reports an insider sale, which can be perceived neutrally to slightly negatively. However, the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which mitigates concerns about the timing or motivation of the sale, indicating it was not based on new, undisclosed material information.
Negatives
- A reduction of 2,572 ordinary shares in the direct beneficial ownership of a key executive.
Future Outlook
No forward-looking statements or guidance are provided in this filing, as it pertains solely to an individual insider transaction.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: A slight reduction in insider ownership, though mitigated by the 10b5-1 plan, which suggests the sale was not based on new, adverse information.
Key Dates
| Date | Description |
|---|---|
| September 20, 2024 | Date the Rule 10b5-1 trading arrangement was entered into by the Reporting Person. |
| July 22, 2025 | Date of the reported transaction (sale of shares). |
| July 23, 2025 | Date the Form 4 was signed by the Reporting Person. |
Recommendation
holdThe filing details a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine transaction and does not typically signal new material information about the company's performance or outlook. Therefore, it does not provide a basis for a change in investment recommendation.
Keywords
Mural Oncology, MURA, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Maiken Keson-Brookes, Chief Legal Officer, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.